Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hurteloup

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Cancer Treatment Reports|October 1, 1987
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemiaJ L Harousseau, P Hurteloup, J Reiffers, et al.
Journal of Pharmaceutical Sciences|December 1, 1991
Improved bioavailability of a new oral preparation of medroxyprogesterone acetateM C Etienne, G Milano, N René, et al.
Leukemia & Lymphoma|July 1, 1996
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphomaP Dufour, R Mors, P Berthaud, et al.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Cancer Treatment Reports|October 1, 1987
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemiaJ L Harousseau, P Hurteloup, J Reiffers, et al.
Journal of Pharmaceutical Sciences|December 1, 1991
Improved bioavailability of a new oral preparation of medroxyprogesterone acetateM C Etienne, G Milano, N René, et al.
Leukemia & Lymphoma|July 1, 1996
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphomaP Dufour, R Mors, P Berthaud, et al.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Pageof 4